Forgot Password?
Return to Course Listing

CME: Retina Updates 2021 (Live Meeting) (RVA)

Activity Description / Statement of Need:

First line providers are the key to early diagnosis and prevention of disease of the retina, macula and vitreous. This meeting will refresh and reaffirm our target audience’s ability to recognize symptoms related to these diseases, or provide new information where knowledge gaps exists, as well as providing learners with tips on how to discuss prevention with their patients. We will also present updates in the field which impact the treatment of these diseases.


Target Audience:

Ophthalmologists and Optometrists

No commercial support.


Release Date: October 17, 2021 -- Expiration Date: November 17, 2021

Faculty: Multiple Faculty,


David S. Boyer, MD
Gene Therapy for Treatment of Wet Macular Degeneration

Thomas G. Chu, MD
Ergonomics in Medicine and Surgery

Firas M. Rahhal, MD
Treatment of Diabetic Retinopathy in 2021

Homayoun Tabandeh, MD
Macular Hole

Pouya N. Dayani, MD
Syphilitic Uveitis

David S. Liao, MD
Cell Based Therapies for Retinitis Pigmentosa

Break / Exhibits

Alex C. Walsh, MD
Ophthalmic Manifestations of Covid-19

Dan D. Esmaili, MD
Vitreo-Macular Traction

Jeffrey J. Tan, MD
Update on Sutureless Sclera-Fixated IOL

Daniel Su, MD
Scleral Sutured IOL (with Goretex) & refractive outcomes

Ramsudha Narala, MD
Pigmented Lesions of Retina and Choroid

Richard H. Roe, MD
DRCR Protocol U - Adjunctive steroids for DME following Anti-VEGF therapy


Learning Objectives

By the end of the session the participant will be able to:

  • Recognize symptoms related to diseases of the Retina, Macula and Vitreous
  • Diagnose patients earlier and slow the vision loss process
  • Discuss treatment options for these diseases with patients, including clinical trials and appropriate referrals
  • Implement new strategies for on early prevention of diseases and increased quality of life with their patients
  • Outline any variations in epidemiology, diagnosis or treatment by age, gender, ethnicity, language, culture or socioeconomic factors



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ScientiaCME and Retina-Vitreous Associates Medical Group. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Faculty Disclosure and Resolution of COI

See program materials.

David Boyer, MD has received financial compensation from:

Acucela Consultant
Adverum Biotech Consultant, Grant Res
Aerie Pharma Grant Rsearch
Aerpio Consultant, Grant Res
Alimera Sciences Consultant
Allegro Consultant
Allergan Consultant, Grant Res
Apellis Consultant, Grant Res
Bayer Consultant
Chengdu Kanghong Consultant, Grant Res

Clearside BiomedicalConsultant, Grant Res
Eyepoint Pharma Consultant
Gemini Therap Consultant
Genentech/ Roche Consultant, Grant Res
GrayBug Vision Consultant
IONIS Pharma Consultant
Kodiak Consultant, Grant Res
Neurotech Consultant
Novartis Consultant, Grant Res
ONL Therap Consultant
Opthea Consultant
Outlook Therap Consultant
Oxurion Consultant
Recens Medical Consultant, Grant Res
Regeneron Consultant, Grant Res
Regenxbio Consultant
Roche Consultant, Grant Res
Santen Consultant, Grant Res
Takeda Consultant

Thomas G. Chu, MD
Nothing to Disclose

Pouya Dayani, MD has received financial compensation from:

Novartis Speakers Bureau

Regeneron Speakers Bureau

Eyepoint Pharma Speakers Bureau

Daniel D. Esmaili, MD has received financial compensation from:

Regeneron Speakers Bureau

David S. Liao, MD
Nothing to Disclose

Ramsudha Narala, MD
Nothing to Disclose

Firas Rahhal, MD has received financial compensation from:

Alcon Advisor
Beaver-Visitec (BVI) Advisor
ReVana Therapeutics Consultant
Zeiss Advisor
Alpine Therapeutics Advisor
Outlook Therap Advisor
ExSight Ventures Stockholder

Richard H. Roe, MD has received financial compensation from:

Alcon Surgical Consultant

Daniel Su, MD
Nothing to Disclose

Homayoun Tabandeh, MD is a stockholder in: Alimera Sciences

Jeffrey J. Tan, MD
Nothing to Disclose

Alexander C. Walsh, MD is Employee/Director and Stockholder of Envision Diagnostics, Inc

Activity Planner Maria Gutierrez has Nothing to Disclose


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.